News
Chinese drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...
IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...
Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.
6h
Zacks Investment Research on MSNMerck's Narrowed 2025 Sales View: What it Means After Q2 Results?Merck MRK announced mixed second-quarter results last month. The company beat estimates for earnings while meeting the same ...
IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...
Arcus Biosciences nears key catalysts with late-stage assets & upcoming Phase 3 data. Discover potential upside & why it's ...
These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
A Newsweek report reveals America's Most Responsible Companies for 2025, with a New Jersey-based company earning the top spot ...
Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.
Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...
The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results